Find, compare & contact
Bryostatin 1
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Bryostatin 1 API 83314-01-6?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Bryostatin 1. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Bryostatin 1
- Synonyms:
- Bryostatin-1
- Cas Number:
- 83314-01-6
- DrugBank number:
- DB11752
- Unique Ingredient Identifier:
- 37O2X55Y9E
General Description:
Bryostatin 1, identified by CAS number 83314-01-6, is a notable compound with significant therapeutic applications. Bryostatin 1 has been investigated for the treatment of HIV Infection and Alzheimer's Disease.
Categories:
Bryostatin 1 is categorized under the following therapeutic classes: Adjuvants, Immunologic, Anti-Bacterial Agents, Antineoplastic Agents, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Enzyme Activation, Immunologic Factors, Lactones, Macrolides. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Bryostatin 1 is a type of Antineoplastics
Antineoplastics are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) primarily used in the treatment of cancer. These powerful substances inhibit or destroy the growth of cancer cells, thus impeding the progression of malignancies.
Antineoplastics exert their therapeutic effects through various mechanisms. Some APIs interfere with DNA replication, inhibiting the division and proliferation of cancer cells. Others target specific proteins or enzymes involved in tumor growth, effectively blocking their function. Additionally, certain antineoplastic agents induce programmed cell death, known as apoptosis, in cancer cells.
These APIs find application in a wide range of cancer treatments, including chemotherapy, targeted therapy, immunotherapy, and hormone therapy. They are often administered in combination with other drugs to optimize therapeutic outcomes and minimize drug resistance.
Antineoplastics are typically synthesized through complex chemical processes, ensuring high purity and potency. Stringent quality control measures are implemented throughout manufacturing to meet regulatory standards and ensure patient safety.
Although antineoplastics offer significant benefits in treating cancer, they can also cause adverse effects due to their cytotoxic nature. Common side effects include bone marrow suppression, gastrointestinal disturbances, hair loss, and immune system suppression. Close monitoring and supportive care are essential to manage these side effects effectively.
In conclusion, antineoplastics are a vital category of pharmaceutical APIs used in the treatment of cancer. Through their diverse mechanisms of action, these compounds play a critical role in combating malignancies and improving patient outcomes.
